Retrospective characterization of the S open reading frame of HBV isolated from children with membranous nephropathy treated with interferon-α2b

Antiviral Therapy

Volumn 15, Issue 1, 2010, Pages 61-69

  Gous, Natasha ^a   Bhimma, Rajendra ^b   Kew, Michael ^a,c   Kramvis, Anna ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ARTICLE; HEPATITIS B; HEPATITIS B VIRUS; MEMBRANOUS GLOMERULONEPHRITIS; MICROBIAL POPULATION DYNAMICS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS GENE; VIRUS MUTATION;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL AGENTS; CHILD; DNA, VIRAL; GENETIC MARKERS; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; MUTATION; OPEN READING FRAMES; PHYLOGENY; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 77949399478     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1487     Document Type: Article

References (49)

1. Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971; 2:234-237.
2. Takekoshi Y, Tanaka M, Shida N, Satake Y, Saheki Y, Matsumoto S. Strong association between membranous nephropathy and hepatitis-B surface antigenaemia in Japanese children. Lancet 1978; 2:1065-1068.
3. Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 2007; 37:S9-S19.
4. Bhimma R, Coovadia HM, Adhikari M. Hepatitis B virusassociated nephropathy in Black South African children. Pediatr Nephrol 1998; 12:479-484.
5. Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50:805-816.
6. Bhimma R, Coovadia HM, Adhikari M, Connolly CA. The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch Pediatr Adolesc Med 2003; 157:1025-1030.
7. Haria M, Benfield P. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995; 50:873-896.
8. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996; 17:369-372.
9. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr 1995; 127:815-818.
10. Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994; 20:287-290.
11. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114:988-995.
12. 2-interferon in Chinese HBsAg-carrier children. Lancet 1987; 2:877-880.
13. Xu J, Brown D, Harrison T, Lin Y, Dusheiko G. Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-alpha. Hepatology 1992; 15:1002-1006.
14. Dusheiko GM, Paterson AC, Pitcher L, et al. Recombinant leucocyte interferon treatment of chronic hepatitis B. An analysis of two therapeutic trials. J Hepatol 1986; 3 Suppl 2:S199-S207.
15. Bhimma R, Coovadia HM, Kramvis A, Adhikari M, Kew MC. Treatment of hepatitis B virus-associated nephropathy in Black children. Pediatr Nephrol 2002; 17:393-399.
16. Aikawa T, Kanai K, Kako M, et al. Interferon-α2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild-type virus and precore mutant. J Viral Hepat 1995; 2:243-250.
17. Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31:716-725.
18. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005; 12:456-464.
19. Yuen MF, Lai CL. Hepatitis B virus genotypes: natural history and implications for treatment. Expert Rev Gastroenterol Hepatol 2007; 1:321-328.
20. Takeda K, Akahane Y, Suzuki H, et al. Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to anti-HBe induced spontaneously or with interferon therapy. Hepatology 1990; 12:1284-1289.
21. Zampino R, Marrone A, Cirillo G, et al. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment. J Viral Hepat 2002; 9:183-188.
22. Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol 2003; 18:630-637.
23. Kimbi GC, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J Gen Virol 2004; 85:1211-1220.
24. Huy TT, Ushijima H, Win KM, et al. High prevalence of hepatitis B virus pre-S mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol 2003; 41:5449-5455.
25. Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Arch Dis Child 1994; 70:151-157.
26. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
27. Owiredu WK, Kramvis A, Kew MC. Hepatitis B virus DNA in serum of healthy Black African adults positive for hepatitis B surface antibody alone: possible association with recombination between genotypes A and D. J Med Virol 2001; 64:441-454.
28. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-largescale analysis using a new genotyping method. J Infect Dis 1997; 175:1285-1293.
29. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans. J Med Virol 2005; 75:513-521.
30. Xia X. Data analysis in molecular biology and evolution. Norwell, MA: Kluwer Academic Publishers 2000.
31. Steinhauer DA, Holland JJ. Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA. J Virol 1986; 57:219-228.
32. Smith DB, McAllister J, Casino C, Simmonds P. Virus 'quasispecies': making a mountain out of a molehill? J Gen Virol 1997; 78:1511-1519.
33. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003; 23:5-20.
34. Domingo E. Quasispecies and the implications for virus persistence and escape. Clin Diagn Virol 1998; 10:97-101.
35. Lauder IJ, Lin HJ, Lau JY, Siu TS, Lai CL. The variability of the hepatitis B virus genome: statistical analysis and biological implications. Mol Biol Evol 1993; 10:457-470.
36. Bowyer SM, Sim JG. Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates. J Gen Virol 2000; 81:379-392.
37. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 1993; 194:137-148.
38. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A 1991; 88:1059-1063.
39. D'Mello F, Partidos CD, Steward MW, Howard CR. Definition of the primary structure of hepatitis B virus (HBV) pre-S hepatocyte binding domain using random peptide libraries. Virology 1997; 237:319-326.
40. Hannoun C, Krogsgaard K, Horal P, Lindh M. Genotype mixtures of hepatitis B virus in patients treated with interferon. J Infect Dis 2002; 186:752-759.
41. Xu H, Peng M, Qing Y, et al. A Quasi Species of the pre-S/S Gene and mutations of enhancer II/Core promoter/pre-C in mothers and their children infected with hepatitis B virus via mother-to-infant transmission. J Infect Dis 2006; 193:88-97.
42. Salisse J, Sureau C. A function essential to viral entry underlies the hepatitis B virus 'a' determinant. J Virol 2009; 83:9321-9328.
43. Khan N, Guarnieri M, Ahn SH, et al. Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol 2004; 78:3262-3270.
44. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25:97-106.
45. Ong HT, Duraisamy G, Kee Peng N, Wen Siang T, Seow HF. Genotyping of hepatitis B virus in Malaysia based on the nucleotide sequence of preS and S genes. Microbes Infect 2005; 7:494-500.
46. Paulij WP, de Wit PL, Sunnen CM, et al. Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. J Gen Virol 1999; 80:2121-2126.
47. Sominskaya I, Paulij W, Jansons J, et al. Fine-mapping of the B-cell epitope domain at the N-terminus of the preS2 region of the hepatitis B surface antigen. J Immunol Methods 2002; 260:251-261.
48. Mimms L. Hepatitis B virus escape mutants: 'pushing the envelope' of chronic hepatitis B virus infection. Hepatology 1995; 21:884-887.
49. Liu CJ, Chen PJ, Lai MY, et al. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. Antivir Ther 2004; 9:895-903.